Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

被引：0
|
作者：
Laiyi Chua
Stuart Friedrich
Xin Cindy Zhang
机构：
[1] Eli Lilly and Company,Global PK/PD and Pharmacometrics
来源：
Clinical Pharmacokinetics | 2023年 / 62卷 / 10期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1479 / 1491
页数：12
相关论文
共 50 条
  • [21] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Otani, Yuki
    Chua, Laiyi
    Komocsar, Wendy
    Larkin, Amy E.
    Zhang, Xin
    GASTROENTEROLOGY, 2024, 166 (05) : S822 - S823
  • [22] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
    Sandborn, W. J.
    Sands, B.
    Kobayashi, T.
    Tuttle, J.
    Schmitz, J.
    Durante, M.
    Higgs, R.
    Canavan, J. B.
    Siegel, R.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60
  • [23] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
    Friedrich, S.
    Chua, L.
    Zhang, X. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646
  • [24] Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
    Fung, Simon
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, : 433 - 443
  • [25] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALS
    Friedrich, Stuart
    Chua, Laiyi
    Zhang, Xin
    GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218
  • [26] Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Watanabe, Mamoru
    Hisamatsu, Tadakazu
    Hirai, Fumihito
    Milata, Joe
    Li, Xingyuan
    Morris, Nathan
    Arora, Vipin
    Ishizuka, Tomoko
    Matsuo, Koji
    Satoi, Yoichi
    Milch, Catherine
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2024, 22 (02) : 172 - 185
  • [27] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [28] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [29] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S10 - S11
  • [30] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    GASTROENTEROLOGY, 2020, 158 (03) : S17 - S18
12345